SOURCE: Alkermes
DESCRIPTION:
We are pleased to share clinical trial data on our investigational #immunooncology therapy and are excited to be a part of the 17th EADO Congress and 2021 World Mobile Congress Interactive Virtual Meeting. https://worldmelanoma2021.com/
KEYWORDS: NASDAQ:ALKS, Alkermes, Immuno-Oncology, 17th EADO Congress, 2021 World Mobile Congress Interactive Virtual Meeting